The shadow of generic challenges has consistently loomed around copyright’s blockbuster drug, Sildenafil, triggering questions about the future of related drug holdings. While initial years saw substantial returns, the patent lapse has opened the way for cheaper alternatives, potentially reducing profitability and presenting a significant danger